Cargando…

Imaging of chemokine receptor CXCR4 expression in culprit and nonculprit coronary atherosclerotic plaque using motion-corrected [(68)Ga]pentixafor PET/CT

PURPOSE: The chemokine receptor CXCR4 is a promising target for molecular imaging of CXCR4(+) cell types, e.g. inflammatory cells, in cardiovascular diseases. We speculated that a specific CXCR4 ligand, [(68)Ga]pentixafor, along with novel techniques for motion correction, would facilitate the in vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Derlin, Thorsten, Sedding, Daniel G., Dutzmann, Jochen, Haghikia, Arash, König, Tobias, Napp, L. Christian, Schütze, Christian, Owsianski-Hille, Nicole, Wester, Hans-Jürgen, Kropf, Saskia, Thackeray, James T., Bankstahl, Jens P., Geworski, Lilli, Ross, Tobias L., Bauersachs, Johann, Bengel, Frank M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6132552/ https://www.ncbi.nlm.nih.gov/pubmed/29967943 http://dx.doi.org/10.1007/s00259-018-4076-2

Ejemplares similares

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Targeting CXCR4 with [(68)Ga]Pentixafor: a suitable theranostic approach in pleural mesothelioma?
por: Lapa, Constantin, et al.
Publicado: (2017)

Visualization of the auditory pathway in rats with (18)F-FDG PET activation studies based on different auditory stimuli and reference conditions including cochlea ablation
por: Mamach, Martin, et al.
Publicado: (2018)

The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Molecular imaging of inflammation crosstalk along the cardio-renal axis following acute myocardial infarction
por: Werner, Rudolf A., et al.
Publicado: (2021)

Normal endothelial but impaired arterial development in MAP-Kinase activated protein kinase 2 (MK2) deficient mice
por: Napp, L. Christian, et al.
Publicado: (2016)

Erratum to: ‘Normal endothelial but impaired arterial development in MAP-Kinase activated protein kinase 2 (MK2) deficient mice’
por: Napp, L. Christian, et al.
Publicado: (2016)

[68Ga]Pentixafor-PET/MRI for the detection of Chemokine receptor 4 expression in atherosclerotic plaques
por: Li, Xiang, et al.
Publicado: (2017)

Rapid progression of nonculprit coronary lesions six weeks after successful primary PCI in culprit artery: a case report
por: Tang, Jianjin, et al.
Publicado: (2014)

Prospective non-invasive evaluation of CXCR4 expression for the diagnosis of MALT lymphoma using [(68)Ga]Ga-Pentixafor-PET/MRI
por: Haug, Alexander R., et al.
Publicado: (2019)

(68)Ga-Pentixafor-PET/CT for Imaging of Chemokine Receptor 4 Expression in Glioblastoma
por: Lapa, Constantin, et al.
Publicado: (2016)

[(68)Ga]Pentixafor PET/MR imaging of chemokine receptor 4 expression in the human carotid artery
por: Li, Xiang, et al.
Publicado: (2019)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor CXCR4 expression in multiple myeloma - Comparison to [(18)F]FDG and laboratory values
por: Lapa, Constantin, et al.
Publicado: (2017)

[(68)Ga]-Pentixafor PET/CT for CXCR4-Mediated Imaging of Vestibular Schwannomas
por: Breun, Maria, et al.
Publicado: (2019)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Targeting Amino Acid Metabolism for Molecular Imaging of Inflammation Early After Myocardial Infarction
por: Thackeray, James T., et al.
Publicado: (2016)

[(68)Ga]Pentixafor-PET/CT for imaging of chemokine receptor 4 expression in small cell lung cancer - initial experience
por: Lapa, Constantin, et al.
Publicado: (2016)

Emerging translational approaches to target STAT3 signalling and its impact on vascular disease
por: Dutzmann, Jochen, et al.
Publicado: (2015)

Interventional Treatment of Nonculprit Lesions in Infarct‐Related Cardiogenic Shock
por: Desch, Steffen, et al.
Publicado: (2019)

Investigation of spleen CXCR4 expression by [(68)Ga]Pentixafor PET in a cohort of 145 solid cancer patients
por: Lewis, Richard, et al.
Publicado: (2021)

Deepening of response to prostate-specific membrane antigen ligand-targeted radioligand therapy beyond end of treatment
por: Derlin, Thorsten, et al.
Publicado: (2021)

Molecular imaging of fibroblast activation protein after myocardial infarction using the novel radiotracer [(68)Ga]MHLL1
por: Langer, Laura B.N., et al.
Publicado: (2021)

CXCR4 PET imaging of mantle cell lymphoma using [(68)Ga]Pentixafor: comparison with [(18)F]FDG-PET
por: Mayerhoefer, Marius E., et al.
Publicado: (2021)

Gender differences in plaque characteristics of nonculprit lesions in patients with coronary artery disease
por: Tian, Jiangtian, et al.
Publicado: (2019)

Pentixafor PET/CT for imaging of chemokine receptor 4 expression in esophageal cancer – a first clinical approach
por: Linde, Philipp, et al.
Publicado: (2021)

Current Status of (68)Ga-Pentixafor in Solid Tumours
por: Hadebe, Bawinile, et al.
Publicado: (2022)

Culprit and Nonculprit Recurrent Ischemic Events in Patients With Myocardial Infarction: Data From SWEDEHEART (Swedish Web System for Enhancement and Development of Evidence‐Based Care in Heart Disease Evaluated According to Recommended Therapies)
por: Varenhorst, Christoph, et al.
Publicado: (2018)

Characterizing the transition from immune response to tissue repair after myocardial infarction by multiparametric imaging
por: Hess, Annika, et al.
Publicado: (2022)

[(68)Ga]pentixafor for CXCR4 imaging in a PC-3 prostate cancer xenograft model – comparison with [(18)F]FDG PET/CT, MRI and ex vivo receptor expression
por: Schwarzenböck, Sarah M., et al.
Publicado: (2017)

The natural course of nonculprit coronary artery lesions; analysis by serial quantitative coronary angiography
por: Kang, Jeehoon, et al.
Publicado: (2018)

Lipoprotein (a) levels and vulnerable characteristics in nonculprit plaque in patients with acute coronary syndrome()
por: Kato, Ayami, et al.
Publicado: (2022)

Reliable quantification of (18)F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio
por: Buchert, Ralph, et al.
Publicado: (2020)

Agreement between nonculprit stenosis follow-up iFR and FFR after STEMI (iSTEMI substudy)
por: Thim, Troels, et al.
Publicado: (2020)

Response assessment with the CXCR4-directed positron emission tomography tracer [(68)Ga]Pentixafor in a patient with extranodal marginal zone lymphoma of the orbital cavities
por: Herhaus, Peter, et al.
Publicado: (2017)

Vasa Vasorum Angiogenesis: Key Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease
por: Sedding, Daniel G., et al.
Publicado: (2018)

Recent Updates on Molecular Imaging Reporting and Data Systems (MI-RADS) for Theranostic Radiotracers—Navigating Pitfalls of SSTR- and PSMA-Targeted PET/CT
por: Werner, Rudolf A., et al.
Publicado: (2019)

Takotsubo syndrome: between evidence, myths, and misunderstandings
por: Napp, L. Christian, et al.
Publicado: (2020)

Comparison of pretherapeutic osseous tumor volume and standard hematology for prediction of hematotoxicity after PSMA-targeted radioligand therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

PSMA Expression Predicts Early Biochemical Response in Patients with Metastatic Castration-Resistant Prostate Cancer under (177)Lu-PSMA-617 Radioligand Therapy
por: Widjaja, Liam, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_2l23on334v2rkvno5dg20pua3f